<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216577</url>
  </required_header>
  <id_info>
    <org_study_id>hOPeFUL</org_study_id>
    <nct_id>NCT03216577</nct_id>
  </id_info>
  <brief_title>Outcomes of Purpura FULminans in Adults - The hOPeFUL Study</brief_title>
  <acronym>hOPeFUL</acronym>
  <official_title>Short and Long-term Outcomes of Purpura Fulminans in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Henri Mondor University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the
      association of a sudden and extensive purpura together with acute circulatory failure. The
      mortality of PF has been reported to be as high as 50% in previous adult series.
      Additionally, patients surviving to the early phase of PF are exposed to a high risk of limb
      amputation. The hOPeFUL study aims at assessing the short and long term outcomes of adult
      patients admitted in the intensive care unit for a purpura fulminans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the
      association of a sudden and extensive purpura together with acute circulatory failure.
      Neisseria meningitidis and Streptococcus pneumoniae are the most frequently involved
      microorganisms but other species (e.g., Staphylococcus aureus, Streptococcus pyogenes,
      Haemophilus influenzae…) have also been reported. Despite prompt antibiotics administration
      and intensive care management, the mortality of PF has been reported to be as high as 50% in
      previous adult series. Additionally, patients surviving to the early phase of PF are exposed
      to a high risk of serious sequelae related to extensive skin necrosis and acral symmetrical
      gangrene, which typically requires limb amputations, a potential source of severe handicap in
      these previously young and healthy patients. Although the clinical features and outcomes of
      PF have been well studied in the pediatric setting, the amount of available data for adult PF
      are scarce, often outdated and mainly limited to patients with meningococcal infections. The
      current study aims at assessing the short and long-term outcomes of adult patients admitted
      in the intensive care unit for a purpura fulminans. A large multicenter retrospective cohort
      will be built in order to assess hospital outcomes (i.e., mortality and amputations).
      Long-term outcomes, including health-related quality variables, will be prospectively
      assessed among survivors and compared to septic controls (i.e., patients having septic shock
      non-related to purpura fulminans).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Actual">March 8, 2018</completion_date>
  <primary_completion_date type="Actual">March 8, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>day 60</time_frame>
    <description>factors associated with hospital mortality (and rate of amputation in the hospital) will be identified using a polytomous logistic regression model</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of amputation in the hospital;</measure>
    <time_frame>day 60</time_frame>
    <description>factors associated with rate of amputation in the hospital (and hospital mortality) will be identified using a polytomous logistic regression model</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term outcome measure: Physical dimension scale of the SF-36 questionnaire</measure>
    <time_frame>Within 6 years of hospital discharge</time_frame>
    <description>This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mental component score of the SF-36 score</measure>
    <time_frame>Within 6 years of hospital discharge</time_frame>
    <description>This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of daily living (ADL score)</measure>
    <time_frame>Within 6 years of hospital discharge</time_frame>
    <description>This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital anxiety and depression scale</measure>
    <time_frame>Within 6 years of hospital discharge</time_frame>
    <description>This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Event Scale</measure>
    <time_frame>Within 6 years of hospital discharge</time_frame>
    <description>This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical dimension scale of the SF-36 questionnaire</measure>
    <time_frame>Within 6 years of hospital discharge</time_frame>
    <description>This variable will be compared between patients with purpura fulminans who were and those who were not amputated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental component score of the SF-36 score</measure>
    <time_frame>Within 6 years of hospital discharge</time_frame>
    <description>This variable will be compared between patients with purpura fulminans who were and those who were not amputated</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">74</enrollment>
  <condition>Purpura Fulminans</condition>
  <arm_group>
    <arm_group_label>Exposed to purpura fulminans</arm_group_label>
    <description>Patients who were admitted in the intensive care unit and survived a purpura fulminans episode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exposed to purpura fulminans</arm_group_label>
    <description>Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phone interview measuring health-related quality of life variables</intervention_name>
    <description>A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.</description>
    <arm_group_label>Exposed to purpura fulminans</arm_group_label>
    <arm_group_label>Non-exposed to purpura fulminans</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted in the intensive care unit between 2010 and 2016 for an infectious
        purpura fulminans (cases/exposed patients) and discharged alive will be matched (gender,
        age and SAPS II score) to patients admitted during the same time frame for a septic shock
        non-related to purpura fulminans (controls/non-exposed pâtients).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted in the intensive care unit between 2010 and 2016 for an infectious
             purpura fulminans and discharged alive

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Non infectious purpura

          -  Infective endocarditis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas de Prost, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aulnay sous Bois Hospital</name>
      <address>
        <city>Aulnay-sous-Bois</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chartres Hospital</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Mourier Hospital</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Roche sur Yon Hospital</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Versailles Hospital</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Havre Hospital</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lilles University Hospital</name>
      <address>
        <city>Lilles</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melun Hospital</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>6003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orléans Hospital</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpétrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bichat University Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poissy Hospital</name>
      <address>
        <city>Poissy</city>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Gallien</name>
      <address>
        <city>Quincy-sous-Sénart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims University Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roubaix Hospital</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Giraud T, Dhainaut JF, Schremmer B, Regnier B, Desjars P, Loirat P, Journois D, Lanore JJ. Adult overwhelming meningococcal purpura. A study of 35 cases, 1977-1989. Arch Intern Med. 1991 Feb;151(2):310-6.</citation>
    <PMID>1992958</PMID>
  </results_reference>
  <results_reference>
    <citation>Lerolle N, Carlotti A, Melican K, Aubey F, Pierrot M, Diehl JL, Caille V, Hékimian G, Gandrille S, Mandet C, Bruneval P, Dumenil G, Borgel D. Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans. Am J Respir Crit Care Med. 2013 Sep 15;188(6):684-92. doi: 10.1164/rccm.201302-0228OC.</citation>
    <PMID>23924269</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henri Mondor University Hospital</investigator_affiliation>
    <investigator_full_name>Nicolas de Prost</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>health-related quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura Fulminans</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

